Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 109Thoracic 8Gynecologic 5Endocrine 4Tumor-Agnostic 3Head & Neck 3Genitourinary 3Dermatologic 3Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2CNS 2Breast 2Sarcoma 1NET 1Myeloid 1

Conditions

Carcinoma, Neuroendocrine 3Neuroendocrine Tumors 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
IFL protocol × Endocrine × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02820857 2025-09-03

BEVANEC

Hospices Civils de Lyon

Phase 2 Completed
153 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Biotheus Inc.

Phase 2 Recruiting
60 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03168607 2017-06-01

Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Peking University

Phase 2 Unknown
45 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡